Dihydroergocryptine (DHEC trade names Almirid Cripar) is a dopamine agonist of the ergoline chemical class that is used as an antiparkinson agent. Dihydroergocryptine has been shown to be particularly effective as monotherapy in the early stages of Parkinson’s disease. Initial monotherapy with a dopamine agonist (other examples include pergolide pramipexole and ropinirole) is associated with reduced risk for motor complications in Parkinson patients relative to levodopa.
This page contains content from the copyrighted Wikipedia article "Dihydroergocryptine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
